Population PK/PD from a Phase I Study of the Single-Agent PARP Inhibitor, Veliparib (ABT-888) in Patients with Cancer

Author(s): C. Scheuerell, S. Karan, B. F. Kiesel, J. Ji, S. Puhalla, J. H. Beumer, J. Gobburu
Year:

Learn More
LinkedIn